0001489393-26-000012
SEC filingLyondellBasell Industries N.V. reported a challenging fiscal year 2025 with sales and other operating revenues of $30.15 billion. The company incurred significant impairments totaling $1.25 billion, including goodwill impairments of $972 million and other impairments of $279 million, contributing to an operating loss of $420 million. Despite generating $2.26 billion in net cash from operating activities, the company reported a net loss of $738 million and a net loss attributable to shareholders of $745 million, resulting in basic and diluted earnings per share of -$2.00. The balance sheet shows total assets of $34.00 billion, with long-term debt of $12.12 billion and total equity of $10.09 billion. Cash flow from operations was strong at $2.26 billion, but significant cash outflows included $1.88 billion in capital expenditures and $1.76 billion in dividends paid.
LyondellBasell Industries N.V. reported a net loss of $738 million for fiscal year 2025, with sales and other operating revenues of $30.15 billion. The company experienced significant challenges, including an operating loss of $420 million driven by substantial impairments totaling $1.25 billion. Net loss attributable to company shareholders was $745 million, resulting in basic and diluted earnings per share of -$2.00. Despite the net loss, the company generated strong operating cash flow of $2.26 billion. The balance sheet shows total assets of $34.00 billion, with cash and cash equivalents of $3.44 billion and long-term debt of $12.12 billion.
Sales and other operating revenues for fiscal year 2025 were $30.15 billion. The document does not provide segment breakdowns, geographic mix, or specific growth drivers for revenue. The XBRL data shows cost of sales was $27.58 billion, with selling, general and administrative expenses of $1.61 billion and research and development expenses of $136 million. No further revenue segmentation or analysis is available in the provided data.
The company reported negative operating margins for fiscal year 2025, with operating loss of $420 million on revenues of $30.15 billion. Significant cost pressures included $1.25 billion in impairments ($972 million goodwill impairment and $279 million other impairments), which substantially impacted profitability. Other operating costs included $1.61 billion in selling, general and administrative expenses and $136 million in research and development expenses. The net loss margin was approximately -2.4% based on the $738 million net loss relative to $30.15 billion in revenue.
Operating cash flow was strong at $2.26 billion despite the net loss, supported by $1.39 billion in depreciation and amortization and $1.25 billion in impairments. Free cash flow, calculated as operating cash flow ($2.26B) minus capital expenditures ($1.88B), was $380 million. The balance sheet shows total assets of $34.00 billion, including $3.44 billion in cash and equivalents, $15.83 billion in property, plant and equipment (net), and $3.96 billion in equity investments. Total liabilities were $23.80 billion, with long-term debt of $12.12 billion and total equity of $10.09 billion, resulting in a debt-to-equity ratio of approximately 1.2:1.
The provided document does not include management guidance, strategic priorities, or specific risk factors for future periods. The filing contains only the financial statements and related XBRL data without forward-looking statements or outlook sections. Investors should refer to additional company communications or subsequent filings for information about management's expectations, strategic initiatives, or identified risk factors affecting future performance.